• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
NIU Jun-xing,HU Li-hong.A research and development overview of Fingolimod[J].Journal Of Pharmaceutical Research,2015,34(12):683-687,698[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3767times   Download 4627次 QR Code for this article
Scan with your phone!
芬戈莫德研发历程概述
钮俊兴,胡立宏
Font:Larger+|Default|Smaller-
(中国科学院上海药物研究所,中药现代化中心,上海 201203)
摘要:
芬戈莫德是以真菌的次级代谢产物ISP-Ⅰ为苗头化合物所研发的免疫调节剂,于2010年被FDA批准上市,用以治疗免疫性疾病多发性硬化症。与传统的免疫抑制剂不同,它不影响淋巴细胞的活化和增殖,主要作用于细胞表面的1-磷酸鞘氨醇(S1P)受体来发挥免疫抑制和免疫调控作用。本文通过梳理芬戈莫德的研发流程,阐述结构优化和改造步骤,为药物化学研究提供经验。
关键词:  芬戈莫德  ISP-Ⅰ  多发性硬化症免疫调节剂
DOI:10.13506/j.cnki.jpr.2015.12.001
基金项目:国家自然科学基金面上项目(No.81473110)
A research and development overview of Fingolimod
NIU Jun-xing,HU Li-hong
(Shanghai Research Center for Modernization of Traditional Chinese Medicine,Shanghai Institute of Materia Medica,Chinese Academy of Sciences)
Abstract:
Fingolimod (FTY720),a novel immunomodulator agent, is developed from ISP-1,which is a secondary metabolites of fungi.It was approved by FDA in 2012 for the treatment of autoimmune disease multiple sclerosis.Unlike the traditional immunosuppressive agents,fingolimod exerts immunosuppressive and immunoregulatory functions mainly through interaction with shhingosine-1-phosphate receptors (S1PR) on the cell surface without affecting activation and proliferation of lymphocyhtes.This article briefly reviewed the development process of fingolimod,elaborate the structural optimization and transformation,in order to provide experience for chemical rsearch.
Key words:  Finglimod  ISP-1  Multiple Sclerosis  Immunomodulator
Today's Visits:511    Total Visits:2383242
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.